secwatch.observer — SEC 8-K summary
======================================

Issuer:     GILEAD SCIENCES, INC. (GILD)
CIK:        0000882095
Form:       8-K
Filed at:   2024-02-02T23:59:59+00:00
Accession:  0001104659-24-010051
Event type: leadership
Sentiment:  neutral
Materiality: 0.40
Item codes: 5.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Gilead appoints Ted Love, MD, to Board of Directors; board expands to 10
------------------------------------------------------------------------

- Dr. Love elected to Board effective February 1, 2024; board size increased from 9 to 10.
- He will serve on Audit Committee beginning after 2024 Annual Meeting, subject to reelection.
- Dr. Love is former CEO of Global Blood Therapeutics and current chair of BIO board.
- He also serves on boards of Royalty Pharma and Structure Therapeutics.
- No arrangement or related-party transactions exist in connection with his appointment.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/882095/000110465924010051/0001104659-24-010051-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/882095/000110465924010051/tm244922d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-24-010051

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer